Feng Fei, Chen Jiannan, Li Rong, Zhu Yunkai, Ma Yanlong, Wang Ziqiao, Wang Yuyan, Gao Zhichao, Yang Lulu, Yu Yin, Liu Yanfeng, Sun Yingjie, Liao Ying, Huang Xinxin, Zhang Qisheng, Huang Yongheng, Qiu Lin, Wu Jiayu, Zhao Jingxian, Liu Chao, Ding Qiang, Xie Youhua, Yuan Zhenghong, Hong Yue, Zhang Ping, Sun Jing, Zhao Jincun, Zhang Rong
Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.
Department of Immunology and Microbiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.
mBio. 2025 Aug 20:e0038525. doi: 10.1128/mbio.00385-25.
The SARS-CoV-2 pandemic and the emergence of novel variants underscore the need to understand host-virus interactions and identify host factors that restrict viral infection. Here, we perform a genome-wide CRISPR knockout screen to identify host restriction factors for SARS-CoV-2, revealing DAZAP2 as a potent antiviral gene. DAZAP2, previously implicated in SARS-CoV-2 restriction, is found to inhibit viral entry by blocking virion fusion with both endolysosomal and plasma membranes. Additionally, DAZAP2 suppresses genomic RNA replication without affecting the primary translation of viral replicases. We demonstrate that DAZAP2 functions as a pan-coronavirus restriction factor across four genera of coronaviruses. Importantly, knockout of enhances SARS-CoV-2 infection in mouse models and in human primary airway epithelial cells, confirming its physiological relevance. Mechanistically, the antiviral activity of DAZAP2 appears to be indirect, potentially through the regulation of host gene expression, as it primarily localizes to the nucleus. Our findings provide new insights into the host defense system against coronaviruses and highlight DAZAP2 as a potential target for host-directed antiviral therapies.IMPORTANCEDuring viral infection, the host defense response is mediated by a variety of host factors through distinct mechanisms that have yet to be fully elucidated. Although was previously implicated in SARS-CoV-2 restriction, its mechanisms of action and relevance remain unclear. In this study, we identify DAZAP2 as a potent pan-coronavirus restriction factor that inhibits viral infection through dual mechanisms: blocking virion fusion with both endolysosomal and plasma membranes, and suppressing genomic RNA replication. We confirm its physiological relevance in host defense using mouse models and primary cell cultures. This study advances our understanding of host-pathogen interactions. Targeting DAZAP2 or its regulatory pathways could provide a new approach to enhance host defense against current and future coronavirus threats.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)大流行以及新变种的出现凸显了了解宿主与病毒相互作用以及识别限制病毒感染的宿主因子的必要性。在此,我们进行了全基因组CRISPR敲除筛选以鉴定SARS-CoV-2的宿主限制因子,发现DAZAP2是一种有效的抗病毒基因。DAZAP2此前被认为与SARS-CoV-2限制有关,它通过阻止病毒粒子与内溶酶体膜和质膜融合来抑制病毒进入。此外,DAZAP2在不影响病毒复制酶初级翻译的情况下抑制基因组RNA复制。我们证明DAZAP2作为一种泛冠状病毒限制因子,对四个冠状病毒属均起作用。重要的是,在小鼠模型和人原代气道上皮细胞中敲除DAZAP2可增强SARS-CoV-2感染,证实了其生理相关性。从机制上讲,DAZAP2的抗病毒活性似乎是间接的,可能是通过调节宿主基因表达,因为它主要定位于细胞核。我们的研究结果为宿主对抗冠状病毒的防御系统提供了新见解,并突出了DAZAP2作为宿主导向抗病毒疗法潜在靶点的地位。
重要性
在病毒感染期间,宿主防御反应由多种宿主因子通过尚未完全阐明的不同机制介导。尽管DAZAP2此前被认为与SARS-CoV-2限制有关,但其作用机制和生理相关性仍不清楚。在本研究中,我们鉴定出DAZAP2是一种有效的泛冠状病毒限制因子,它通过双重机制抑制病毒感染:阻止病毒粒子与内溶酶体膜和质膜融合,以及抑制基因组RNA复制。我们使用小鼠模型和原代细胞培养证实了其在宿主防御中的生理相关性。这项研究推进了我们对宿主-病原体相互作用的理解。靶向DAZAP2或其调控途径可为增强宿主对当前及未来冠状病毒威胁的防御提供新方法。